Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors

肿瘤微环境的衰老相关分泌表型 (SASP) 调节作为 KRAS 驱动肿瘤的治疗策略

• 批准号: 9805196
• 负责人: Marcus A. Ruscetti
• 金额: $ 13.71万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-01 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9805196
• 关键词: Ablation; Academia; Advisory Committees; Antigen Presentation; Antigens; Award; Biological; Biology; Bypass; CDK4 gene; CTLA4 gene; Cancer Biology; Cancer Etiology; Cell Aging; Cell Communication; Cell Cycle Arrest; Cells; Cessation of life; Characteristics; Clinic; Cytotoxic Chemotherapy; Disease; Effectiveness; Endothelial Cells; Engineering; Environment; Faculty; Fibroblasts; Functional disorder; Funding Mechanisms; Genetic; Genetic Transcription; Genetically Engineered Mouse; Goals; Human; Imagery; Immune; Immune system; Immunity; Immunologic Surveillance; Immunooncology; Immunosuppression; In Vitro; Individual; Infiltration; International; Intervention; Interview; KRAS2 gene; Label; Lung Neoplasms; MEKs; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Mediating; Memorial Sloan-Kettering Cancer Center; Mentors; Methods; Modeling; Molecular; Molecular Target; Monitor; NK Cell Activation; Natural Killer Cells; Organ; Pathway interactions; Patients; Pharmacology; Phenotype; Positioning Attribute; Predisposition; Premalignant Cell; Process; Production; Protein p53; Reporter; Research; Research Proposals; Resources; Role; SLEB2 gene; Signal Transduction; Solid Neoplasm; Stromal Neoplasm; T cell response; TP53 gene; The Sun; Therapeutic; Time; Tissues; Training Programs; Tumor Antigens; Tumor Suppressor Proteins; United States; Vascular remodeling; Vascularization; Work; Xenograft Model; cancer cell; cancer therapy; career; career development; clinically relevant; disorder control; effective therapy; flexibility; immune checkpoint blockade; immunoregulation; improved; in vivo; inhibitor/antagonist; intravital microscopy; molecular targeted therapies; mouse model; mutant; neoplastic cell; novel therapeutic intervention; pancreatic cancer cells; pancreatic neoplasm; patient subsets; pleiotropism; programs; recruit; response; restoration; screening; senescence; standard of care; targeted agent; therapy outcome; treatment response; tumor; tumor initiation; tumor microenvironment; tumorigenesis

PROJECT SUMMARY/ABSTRACT This proposal describes a training program to advance my academic career in the study of the tumor suppressive barriers that are bypassed during progression to malignancy and how they can be restored for therapeutic benefit in established tumors. Cellular senescence, a tumor suppressive process involving durable cell cycle arrest and activation of a senescence-associated secretory phenotype (SASP), can recruit immune cells to target and clear tumors. During my postdoctoral work, I identified molecularly targeted agents that can reestablish senescence, SASP, and a unique form of Natural Killer (NK) immune surveillance that drives tumor regressions and long-term survival in KRAS mutant lung cancer. This research proposal aims to characterize and exploit the SASP to sustain immune and stromal control of RAS-driven solid tumors, with the goal of identifying new or potentiating existing therapies for these deadly diseases. My expertise in mouse modeling, target discovery, and the biology of senescence and immune surveillance that I have acquired during my postdoctoral studies puts me in a unique position to significantly contribute to elucidating the role of senescence in cancer therapy and identifying new therapeutic strategies for KRAS mutant tumors. To accomplish the research outlined in this application, I will leverage modular and immune competent mouse models of KRAS mutant lung and pancreas cancer, as well as methods to reestablish senescence, SASP, and NK cell immune surveillance that I have already developed in the Lowe lab. In Aim 1, with the hypothesis that methods to overcome NK cell dysfunction are needed to establish disease control, I will explore mechanisms and strategies to further potentiate NK cell responses in KRAS mutant lung cancer through transcriptional and immune profiling and functional screening. In Aim 2, the organ-specific and pleiotropic effects of the SASP on tumor-stromal interactions in pancreas tumors will be interrogated to determine SASP factors necessary for productive tumor control and how they impact the efficacy of standard-of-care therapies. Together, these approaches will unveil new ways by which the SASP can be used to control KRAS-driven tumors. To achieve the goals of this award, I will be mentored by Dr. Scott Lowe and guided by an exceptional advisory committee I have established at MSKCC. Dr. Lowe is an internationally recognized expert in cancer biology, and is focused on understanding tumor suppressor networks through the use of sophisticated mouse models. The advisory committee, constituted by Dr. Lowe, Dr. Sun, Dr. Rosen, Dr. Iacobuzio-Donahue, and Dr. Rudin will monitor and support my transition to independence. Moreover, they will provide invaluable guidance during the process of applying and interviewing for faculty positions. MSKCC will provide me institutional support, including resources for experimental work and career development, as well as an engaging scientific environment. My objective is to obtain a faculty position to develop an impactful research program, where the K99/R00 funding mechanism will serve as an essential step in my transition to independence in academia. ! ! !

项目摘要/摘要 该建议描述了一项培训计划，以提高我在研究肿瘤方面的学术生涯 抑制性障碍在进展为恶性肿瘤期间被绕开，以及如何恢复它们 既定肿瘤的治疗益处。细胞衰老，涉及耐用的肿瘤抑制过程 细胞周期停滞和与衰老相关的分泌表型（SASP）的激活，可以募集免疫 细胞靶向和清除肿瘤。在博士后工作中，我确定了可以分子靶向的剂 重新建立衰老，SASP和一种独特的自然杀手（NK）免疫监视的形式 KRAS突变肺癌的肿瘤回归和长期存活。该研究建议旨在 表征和利用SASP以维持对RAS驱动的实体瘤的免疫和基质控制，并具有 确定这些致命疾病的新现有疗法或增强现有疗法的目标。我在鼠标方面的专业知识 我已经获得的建模，目标发现以及衰老和免疫监测的生物学 在博士后研究中，我处于独特的位置，可以显着促进阐明 癌症治疗中的衰老并确定KRAS突变肿瘤的新治疗策略。 为了完成此应用程序中概述的研究，我将利用模块化和免疫能力的鼠标 KRAS突变肺和胰腺癌的模型，以及重新建立衰老，SASP和 我已经在Lowe Lab中已经开发的NK细胞免疫监测。在AIM 1中，假设 需要克服NK细胞功能障碍的方法来建立疾病控制，我将探索机制 以及通过转录和 免疫分析和功能筛查。在AIM 2中，SASP的器官特异性和多效效应 胰腺肿瘤中的肿瘤肿瘤相互作用将受到询问，以确定SASP因素所需的SASP因素 生产性肿瘤控制及其如何影响护理标准疗法的功效。在一起，这些 方法将推出SASP可用于控制KRAS驱动肿瘤的新方法。 为了实现该奖项的目标，我将得到Scott Lowe博士的指导，并在杰出的咨询中指导 我在MSKCC成立的委员会。 Lowe博士是国际公认的癌症生物学专家， 并专注于通过使用复杂的小鼠模型来理解肿瘤抑制网络。 咨询委员会由Lowe博士，Sun博士，Rosen博士，Iacobuzio-Donahue博士和Rudin博士组成。 将监视和支持我向独立的过渡。此外，他们将在 申请和面试担任教师职位的过程。 MSKCC将为我提供机构支持， 包括用于实验工作和职业发展的资源，以及引人入胜的科学 环境。我的目标是获得教师职位，以制定有影响力的研究计划， K99/R00资金机制将是我过渡到学术界独立的重要一步。 呢 呢 呢